News | Proton Therapy | March 30, 2016

Center with Proteus One system scheduled to open in 2018

IBA, Belgium, first proton therapy center, UZ Leuven, KU Leuven, Proteus One

March 30, 2016 — IBA (Ion Beam Applications SA) announced it has signed a contract with the University Hospitals Leuven (UZ Leuven) and Katholieke Universiteit Leuven (KU Leuven) to install Belgium’s first proton therapy center. The project will be conducted in collaboration with Université Catholique de Louvain (UCL), Cliniques universitaires Saint-Luc and other Belgian universities. IBA was awarded the contract following a comprehensive European public tender conducted by UZ Leuven.

IBA will equip the new center with its Proteus One system. The contract will also include a long-term maintenance agreement. The typical end-user price for a Proteus One system with such a maintenance contract is between EUR 35 and 40 million. This new center is expected to open in 2018.

Marc Decramer, chief executive officer of UZ Leuven, commented, “We are very pleased to announce that we will be working with IBA. The UZ Leuven mission is to deliver the highest quality and most innovative patient care with unrelenting attention to clinical excellence, patient care and patient safety. It was therefore a natural decision for us to equip our hospital with a proton therapy solution as it is the most targeted treatment in the fight against cancer. Following a comprehensive public tender, we have chosen IBA because it provided the proton therapy solution that best fitted our needs.”

In proton therapy, protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor, sparing healthy surrounding tissue. Higher doses can be delivered to the tumor without increasing the risk of side effects and long-term complications, thereby improving patient outcomes and quality of life.

Proteus One is equipped with pencil beam scanning, a technology that offers a millimeter precision treatment, delivered with very high levels of conformity and dose uniformity, even in complex-shaped tumors, whilst at the same time sparing the surrounding healthy tissue.

For more information: www.iba-worldwide.com


Related Content

News

Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...

Time August 09, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 30, 2024
arrow
News | Radiation Oncology

July 11, 2024 — The American Society for Radiation Oncology (ASTRO) issued the following statement from Jeff M ...

Time July 11, 2024
arrow
News | Radiation Oncology

July 9, 2024 — Insights from the latest Mordor Intelligence report, “Radiotherapy Market Size & Share Analysis - Growth ...

Time July 09, 2024
arrow
News | Prostate Cancer

July 5, 2024 — Lantheus Holdings, Inc., a leading radiopharmaceutical-focused company committed to enabling clinicians ...

Time July 05, 2024
arrow
News | Radiology Business

July 3, 2024 — The American Society of Radiologic Technologists has launched the BeRAD Professionalism Award to ...

Time July 03, 2024
arrow
News | Prostate Cancer

July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning ...

Time July 02, 2024
arrow
News | Radiation Oncology

June 3, 2024 — The American Society for Radiation Oncology (ASTRO) published an updated clinical guideline that details ...

Time June 03, 2024
arrow
News | Oncology Information Management Systems (OIMS)

May 30, 2024 — RaySearch Laboratories AB announced the release of the latest version of RayCare, the next generation ...

Time May 30, 2024
arrow
Subscribe Now